NuvaRing Coming Under Fire for Dangerous Effects


Approved by the Food and Drug Administration (FDA) in October 2001, NuvaRing, a low-estrogen contraceptive device has now been linked to blood clots in women. NuvaRing is a flexible, soft, two-inch vaginal ring that is worn for three weeks and then removed for one week. It combines ethinyl etradiol (the estrogen hormone component) and etonogestrel (the progestin hormone component).

Back in December 2007, the safety of the NuvaRing was discussed as The American Society of Hematology found that there were there cases of women who developed complications including blood clots while using NuvaRing.
Side Effects of Nuva Ring:

Blood clots
Heart Attacks
Myocardial infarction
Pulmonary embolism

If you or a loved one has suffered adverse effects after using the NuvaRing contraceptive device, please contact an experienced medical device attorney in your area today.